DaVita Inc

DVA: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
LOCK|bqLOCK|FQG%>LOCK|B&Fjb!^

DaVita Earnings: No Change to 2025 Outlook Despite Cyberattack

In the quarter, DaVita showed revenue growth of 5%, but adjusted earnings per share declined 12% on elevated costs per patient, including pharmaceutical costs. With the help of share repurchases and other controls, DaVita kept its outlook for adjusted EPS and free cash flow intact for the full year.

Sponsor Center